Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age range 21-75,~* diagnosis of alcohol dependence according to DSM-IV criteria~* the presence of AWS as assessed by Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) scale, a scoring system for quantitative evaluation of physical symptoms of AWS.20 Only subjects with a CIWA-Ar score equal to or higher than 10 (defined as moderate or severe AWS requiring pharmacological treatment) were ultimately enrolled in the study.~Exclusion criteria:~* ≤55 kg of body weight;~* history of withdrawal fits within 24 hours pre-study;~* history of epilepsy or epileptics seizures not properly controlled by established anti-epileptic treatment;~* dependence from narcotics, BDZs or other drugs of abuse;~* documented pre-existent hypersensitivity to SMO or to BDZs,~* renal failure (blood creatinine \>2•5 mg/dl and/or documented proteinuria \>500 mg/die),~* heart failure,~* severe respiratory failure~* hepatic encephalopathy stage II-IV;~* psychiatric disorders requiring treatment with psychoactive medications before the start of the study;~* treatment with clonidine, haloperidol, bromocriptine during the last 3 months prior to participation in the study;~* participation to other clinical investigations in the previous month prior to recruitment;~* females whose could not assure not to become pregnant during the 1 month period of treatment, and during the subsequent 3 weeks;~* subjects without a stable social condition or homeless.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sodium oxybate (SMO) (Type: EXPERIMENTAL): Patients randomized to the first arm of the study will receive:~* SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is \> 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~* placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10.
- Oxazepam (Type: ACTIVE_COMPARATOR): Patients randomized to the second arm of the study will receive:~* OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~* placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is \> 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml).

Based on this trial design, predict the completion outcome and termination type (if applicable).